Your shopping cart is currently empty

Hexahydrocurcumin is a selective, orally active COX-2 inhibitor and inactive against COX-1.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $81 | In Stock | In Stock | |
| 5 mg | $198 | In Stock | In Stock | |
| 10 mg | $328 | In Stock | In Stock | |
| 25 mg | $662 | In Stock | In Stock | |
| 50 mg | $987 | In Stock | In Stock | |
| 100 mg | $1,390 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $327 | In Stock | In Stock |
| Description | Hexahydrocurcumin is a selective, orally active COX-2 inhibitor and inactive against COX-1. |
| In vitro | Hexahydrocurcumin (0-25 μM; 24-48 hours; HT-29 cells) significantly decreased HT-29 colon cancer cell viability in a time- and concentration-dependent manner, with IC50 values of 77.05 μM at 24 hours and 56.95 μM at 48 hours. When combined with 5-fluorouracil (5-FU; 5 μM), Hexahydrocurcumin markedly reduced COX-2 expression without altering COX-1 levels [1]. Moreover, Hexahydrocurcumin (7-14 μM; 24 hours) attenuated LPS-induced prostaglandin E2 (PGE2) increase in murine macrophages (RAW 264.7) in a concentration-dependent manner [2]. |
| In vivo | In colon cancer rats, Hexahydrocurcumin (50 mg/kg; oral administration; daily; for 16 weeks; male Wistar rats) treatment significantly reduces the numbers of aberrant crypt foci. Hexahydrocurcumin also markedly decreases COX-2 protein expression [3]. |
| Cell Research | Cell Line: HT-29 cells. Concentration: 0 μM, 5 μM, 10 μM, 25 μM. Incubation Time: 24 hours or 48 hours [1] |
| Animal Research | Animal Model: Male Wistar rats (100-120 g) injected with dimethylhydrazine (DMH). Dosage: 50 mg/kg. Administration: Oral administration; daily; for 16 weeks [3] |
| Molecular Weight | 374.43 |
| Formula | C21H26O6 |
| Cas No. | 36062-05-2 |
| Smiles | COc1cc(CCC(O)CC(=O)CCc2ccc(O)c(OC)c2)ccc1O |
| Relative Density. | 1.226 g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 150 mg/mL (400.61 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.34 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.